Breadcrumb Home Resources and Information Physicians and Scientists Resource Hub Update of The Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due To Mutations Is Rare Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare Blood , Nov 2024 Yeung D et al. Blood, November 2024 Link to full abstract Share Tweet Share Share